Drug Profile
Rizatriptan orally-dissolving film - NAL Pharma
Alternative Names: NAL-1606; Rizatriptan benzoate - NAL Pharma; Rizatriptan ODFLatest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Antimigraines; Small molecules; Triazoles; Tryptamines
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Migraine
Highest Development Phases
- Clinical Phase Unknown Migraine
Most Recent Events
- 26 May 2022 Rizatriptan orally-dissolving film is still in clinical trials for Migraine in Hong Kong (NAL Pharma pipeline, May 2022)
- 28 May 2019 No recent reports of development identified for clinical-Phase-Unknown development in Migraine in Hong Kong (Sublingual, Film)
- 28 Apr 2016 Chemical structure information added